# Validating Natural Compounds as Toll-Like Receptor 4 (TLR4) Antagonists: Experimental Challenges and Therapeutic Perspectives

## TL;DR

This paper reviews natural compounds that may act as TLR4 antagonists and identifies new drug development opportunities.

## Contribution

The study proposes new ligand scaffolds and pharmacophores for TLR4 antagonists based on structural analysis.

## Key findings

- Most natural compounds' direct interaction with TLR4 remains unproven.
- Common binding motifs in TLR4/MD-2 were identified through docking calculations.
- Structure–activity relationships were proposed for drug development.

## Abstract

The activation of TLR4 by endogenous damage or danger-associated
molecular patterns (DAMPs) suggested the use of TLR4 antagonists to
target acute and chronic inflammatory diseases. In recent years, hundreds
of natural compounds (NCs) have been screened for their activity as
TLR4 antagonists. However, the direct interaction with TLR4 or TLR4/MD-2
dimer has not been proven for most of the natural molecules, and their
mechanism of action has been only partially investigated. We review
the recent literature on NCs active as TLR4 antagonists, analyzing
the limitations and selecting among all candidates the compounds presenting
new scaffolds desirable for drug development. After selecting a collection
of representative hit structures, we also present novel docking calculations
on TLR4/MD-2. Our analysis allowed the detection of common binding
motifs in the receptor and the proposal of a structure–activity
relationship from the ligands, enabling the discovery of new ligand
scaffolds and pharmacophores for further development of drug hits.